191 related articles for article (PubMed ID: 37740039)
1. Loss of PDE4D7 expression promotes androgen independence, neuroendocrine differentiation and alterations in DNA repair: implications for therapeutic strategies.
Gulliver C; Huss S; Semjonow A; Baillie GS; Hoffmann R
Br J Cancer; 2023 Oct; 129(9):1462-1476. PubMed ID: 37740039
[TBL] [Abstract][Full Text] [Related]
2. The cAMP phosphodiesterase-4D7 (PDE4D7) is downregulated in androgen-independent prostate cancer cells and mediates proliferation by compartmentalising cAMP at the plasma membrane of VCaP prostate cancer cells.
Henderson DJ; Byrne A; Dulla K; Jenster G; Hoffmann R; Baillie GS; Houslay MD
Br J Cancer; 2014 Mar; 110(5):1278-87. PubMed ID: 24518597
[TBL] [Abstract][Full Text] [Related]
3. Validation of Cyclic Adenosine Monophosphate Phosphodiesterase-4D7 for its Independent Contribution to Risk Stratification in a Prostate Cancer Patient Cohort with Longitudinal Biological Outcomes.
Alves de Inda M; van Strijp D; den Biezen-Timmermans E; van Brussel A; Wrobel J; van Zon H; Vos P; Baillie GS; Tennstedt P; Schlomm T; Houslay MD; Bangma C; Hoffmann R
Eur Urol Focus; 2018 Apr; 4(3):376-384. PubMed ID: 28753810
[TBL] [Abstract][Full Text] [Related]
4. cAMP-phosphodiesterase 4D7 (PDE4D7) forms a cAMP signalosome complex with DHX9 and is implicated in prostate cancer progression.
Gulliver C; Busiau T; Byrne A; Findlay JE; Hoffmann R; Baillie GS
Mol Oncol; 2024 Mar; 18(3):707-725. PubMed ID: 38126155
[TBL] [Abstract][Full Text] [Related]
5. Human ASH-1 promotes neuroendocrine differentiation in androgen deprivation conditions and interferes with androgen responsiveness in prostate cancer cells.
Rapa I; Volante M; Migliore C; Farsetti A; Berruti A; Vittorio Scagliotti G; Giordano S; Papotti M
Prostate; 2013 Aug; 73(11):1241-9. PubMed ID: 23657976
[TBL] [Abstract][Full Text] [Related]
6. Creating a potential diagnostic for prostate cancer risk stratification (InformMDx™) by translating novel scientific discoveries concerning cAMP degrading phosphodiesterase-4D7 (PDE4D7).
Henderson DJP; Houslay MD; Bangma CH; Hoffmann R
Clin Sci (Lond); 2019 Jan; 133(2):269-286. PubMed ID: 30683712
[TBL] [Abstract][Full Text] [Related]
7. Human phosphodiesterase 4D7 (PDE4D7) expression is increased in TMPRSS2-ERG-positive primary prostate cancer and independently adds to a reduced risk of post-surgical disease progression.
Böttcher R; Henderson DJ; Dulla K; van Strijp D; Waanders LF; Tevz G; Lehman ML; Merkle D; van Leenders GJ; Baillie GS; Jenster G; Houslay MD; Hoffmann R
Br J Cancer; 2015 Nov; 113(10):1502-11. PubMed ID: 26575822
[TBL] [Abstract][Full Text] [Related]
8. Androgen receptor and chemokine receptors 4 and 7 form a signaling axis to regulate CXCL12-dependent cellular motility.
Hsiao JJ; Ng BH; Smits MM; Wang J; Jasavala RJ; Martinez HD; Lee J; Alston JJ; Misonou H; Trimmer JS; Wright ME
BMC Cancer; 2015 Mar; 15():204. PubMed ID: 25884570
[TBL] [Abstract][Full Text] [Related]
9. [The influence of neuroendocrine differentiation on the growth and androgen receptor expression of prostate carcinoma cells].
Song Y; Wu G; Xin DQ; Na YQ
Zhonghua Wai Ke Za Zhi; 2004 Dec; 42(23):1453-6. PubMed ID: 15733464
[TBL] [Abstract][Full Text] [Related]
10. Induction of FLIP expression by androgens protects prostate cancer cells from TRAIL-mediated apoptosis.
Raclaw KA; Heemers HV; Kidd EM; Dehm SM; Tindall DJ
Prostate; 2008 Nov; 68(15):1696-706. PubMed ID: 18726983
[TBL] [Abstract][Full Text] [Related]
11. From AR to c-Met: androgen deprivation leads to a signaling pathway switch in prostate cancer cells.
Liu T; Mendes DE; Berkman CE
Int J Oncol; 2013 Oct; 43(4):1125-30. PubMed ID: 23877345
[TBL] [Abstract][Full Text] [Related]
12. Wnt-11 promotes neuroendocrine-like differentiation, survival and migration of prostate cancer cells.
Uysal-Onganer P; Kawano Y; Caro M; Walker MM; Diez S; Darrington RS; Waxman J; Kypta RM
Mol Cancer; 2010 Mar; 9():55. PubMed ID: 20219091
[TBL] [Abstract][Full Text] [Related]
13. Sphingosine kinase-1 is central to androgen-regulated prostate cancer growth and survival.
Dayon A; Brizuela L; Martin C; Mazerolles C; Pirot N; Doumerc N; Nogueira L; Golzio M; Teissié J; Serre G; Rischmann P; Malavaud B; Cuvillier O
PLoS One; 2009 Nov; 4(11):e8048. PubMed ID: 19956567
[TBL] [Abstract][Full Text] [Related]
14. Valproic acid induces neuroendocrine differentiation and UGT2B7 up-regulation in human prostate carcinoma cell line.
Valentini A; Biancolella M; Amati F; Gravina P; Miano R; Chillemi G; Farcomeni A; Bueno S; Vespasiani G; Desideri A; Federici G; Novelli G; Bernardini S
Drug Metab Dispos; 2007 Jun; 35(6):968-72. PubMed ID: 17371798
[TBL] [Abstract][Full Text] [Related]
15. Human PDE4D isoform composition is deregulated in primary prostate cancer and indicative for disease progression and development of distant metastases.
Böttcher R; Dulla K; van Strijp D; Dits N; Verhoef EI; Baillie GS; van Leenders GJ; Houslay MD; Jenster G; Hoffmann R
Oncotarget; 2016 Oct; 7(43):70669-70684. PubMed ID: 27683107
[TBL] [Abstract][Full Text] [Related]
16. Mitochondrial DNA depletion reduces PARP-1 levels and promotes progression of the neoplastic phenotype in prostate carcinoma.
Moro L; Arbini AA; Marra E; Greco M
Cell Oncol; 2008; 30(4):307-22. PubMed ID: 18607066
[TBL] [Abstract][Full Text] [Related]
17. Androgens modify therapeutic response to cabazitaxel in models of advanced prostate cancer.
Begemann D; Wang Y; Yang W; Kyprianou N
Prostate; 2020 Sep; 80(12):926-937. PubMed ID: 32542812
[TBL] [Abstract][Full Text] [Related]
18. NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice.
Jin RJ; Wang Y; Masumori N; Ishii K; Tsukamoto T; Shappell SB; Hayward SW; Kasper S; Matusik RJ
Cancer Res; 2004 Aug; 64(15):5489-95. PubMed ID: 15289359
[TBL] [Abstract][Full Text] [Related]
19. 6-(3,4-Dihydro-1H-isoquinoline-2-yl)-N-(6-methoxypyridine-2-yl) nicotinamide-26 (DIMN-26) decreases cell proliferation by induction of apoptosis and downregulation of androgen receptor signaling in human prostate cancer cells.
Choi HE; Shin JS; Leem DG; Kim SD; Cho WJ; Lee KT
Chem Biol Interact; 2016 Dec; 260():196-207. PubMed ID: 27720946
[TBL] [Abstract][Full Text] [Related]
20. Longitudinal analysis of androgen deprivation of prostate cancer cells identifies pathways to androgen independence.
D'Antonio JM; Ma C; Monzon FA; Pflug BR
Prostate; 2008 May; 68(7):698-714. PubMed ID: 18302219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
